Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis

Atsushi Tanaka, Hiroshi Tsukamoto, Hiroki Mitoma, Chikako Kiyohara, Naoyasu Ueda, Masahiro Ayano, Shun ichiro Ohta, Yasutaka Kimoto, Mitsuteru Akahoshi, Yojiro Arinobu, Hiroaki Niiro, Yoshifumi Tada, Takahiko Horiuchi, Koichi Akashi

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)

抄録

Introduction: Progranulin (PGRN), a pleiotropic growth factor, has emerged as an immunoregulatory molecule. Because the roles of PGRN in dermatomyositis (DM) are still unknown, we investigated whether serum PGRN levels are associated with disease activity and prognosis in DM patients, particularly in those with DM complicated with interstitial lung disease (ILD). Methods: The serum levels of PGRN were measured by enzyme-linked immunosorbent assay in patients with DM (n =57; acute/subacute interstitial pneumonia (A/SIP): n =17, chronic interstitial pneumonia (CIP): n =24, without ILD: n =16), polymyositis (PM, n =21; including 6 with ILD) and normal healthy controls (NHCs, n =60). We assessed the correlation between the serum PGRN levels and the activity indexes of ILD or prognosis in DM patients with ILD. Results: Serum PGRN levels were significantly higher in DM patients than in PM patients (P =0.0025) and in NHCs (P <0.0001). In DM patients, the levels were significantly higher in patients with A/SIP than in those with CIP (P <0.0001) or without ILD (P =0.0003). The serum PGRN levels in DM patients with ILD significantly correlated with serum ferritin (r S =0.77, P <0.0001), lactate dehydrogenase (r S =0.54, P =0.0003) and C-reactive protein (r S =0.48, P =0.0015) levels. Moreover, in DM patients with ILD, the cumulative survival rate for 6 months was significantly lower in the group with serum PGRN levels ≥200 ng/ml (67%) than in the group with serum PGRN levels <200 ng/ml (100%) (P =0.0009). Conclusions: Serum PGRN is associated with disease activity and prognosis of DM with ILD. PGRN may play a role in the pathogenesis of DM and could be a useful biomarker.

元の言語英語
記事番号27
ジャーナルArthritis Research and Therapy
17
発行部数1
DOI
出版物ステータス出版済み - 12 14 2015

Fingerprint

Dermatomyositis
Interstitial Lung Diseases
Serum
Polymyositis
Protein S
Ferritins
L-Lactate Dehydrogenase
C-Reactive Protein
Intercellular Signaling Peptides and Proteins
Survival Rate

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

これを引用

@article{687beedda9e443e0a102bbc5df61bf09,
title = "Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis",
abstract = "Introduction: Progranulin (PGRN), a pleiotropic growth factor, has emerged as an immunoregulatory molecule. Because the roles of PGRN in dermatomyositis (DM) are still unknown, we investigated whether serum PGRN levels are associated with disease activity and prognosis in DM patients, particularly in those with DM complicated with interstitial lung disease (ILD). Methods: The serum levels of PGRN were measured by enzyme-linked immunosorbent assay in patients with DM (n =57; acute/subacute interstitial pneumonia (A/SIP): n =17, chronic interstitial pneumonia (CIP): n =24, without ILD: n =16), polymyositis (PM, n =21; including 6 with ILD) and normal healthy controls (NHCs, n =60). We assessed the correlation between the serum PGRN levels and the activity indexes of ILD or prognosis in DM patients with ILD. Results: Serum PGRN levels were significantly higher in DM patients than in PM patients (P =0.0025) and in NHCs (P <0.0001). In DM patients, the levels were significantly higher in patients with A/SIP than in those with CIP (P <0.0001) or without ILD (P =0.0003). The serum PGRN levels in DM patients with ILD significantly correlated with serum ferritin (r S =0.77, P <0.0001), lactate dehydrogenase (r S =0.54, P =0.0003) and C-reactive protein (r S =0.48, P =0.0015) levels. Moreover, in DM patients with ILD, the cumulative survival rate for 6 months was significantly lower in the group with serum PGRN levels ≥200 ng/ml (67{\%}) than in the group with serum PGRN levels <200 ng/ml (100{\%}) (P =0.0009). Conclusions: Serum PGRN is associated with disease activity and prognosis of DM with ILD. PGRN may play a role in the pathogenesis of DM and could be a useful biomarker.",
author = "Atsushi Tanaka and Hiroshi Tsukamoto and Hiroki Mitoma and Chikako Kiyohara and Naoyasu Ueda and Masahiro Ayano and Ohta, {Shun ichiro} and Yasutaka Kimoto and Mitsuteru Akahoshi and Yojiro Arinobu and Hiroaki Niiro and Yoshifumi Tada and Takahiko Horiuchi and Koichi Akashi",
year = "2015",
month = "12",
day = "14",
doi = "10.1186/s13075-015-0547-z",
language = "English",
volume = "17",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis

AU - Tanaka, Atsushi

AU - Tsukamoto, Hiroshi

AU - Mitoma, Hiroki

AU - Kiyohara, Chikako

AU - Ueda, Naoyasu

AU - Ayano, Masahiro

AU - Ohta, Shun ichiro

AU - Kimoto, Yasutaka

AU - Akahoshi, Mitsuteru

AU - Arinobu, Yojiro

AU - Niiro, Hiroaki

AU - Tada, Yoshifumi

AU - Horiuchi, Takahiko

AU - Akashi, Koichi

PY - 2015/12/14

Y1 - 2015/12/14

N2 - Introduction: Progranulin (PGRN), a pleiotropic growth factor, has emerged as an immunoregulatory molecule. Because the roles of PGRN in dermatomyositis (DM) are still unknown, we investigated whether serum PGRN levels are associated with disease activity and prognosis in DM patients, particularly in those with DM complicated with interstitial lung disease (ILD). Methods: The serum levels of PGRN were measured by enzyme-linked immunosorbent assay in patients with DM (n =57; acute/subacute interstitial pneumonia (A/SIP): n =17, chronic interstitial pneumonia (CIP): n =24, without ILD: n =16), polymyositis (PM, n =21; including 6 with ILD) and normal healthy controls (NHCs, n =60). We assessed the correlation between the serum PGRN levels and the activity indexes of ILD or prognosis in DM patients with ILD. Results: Serum PGRN levels were significantly higher in DM patients than in PM patients (P =0.0025) and in NHCs (P <0.0001). In DM patients, the levels were significantly higher in patients with A/SIP than in those with CIP (P <0.0001) or without ILD (P =0.0003). The serum PGRN levels in DM patients with ILD significantly correlated with serum ferritin (r S =0.77, P <0.0001), lactate dehydrogenase (r S =0.54, P =0.0003) and C-reactive protein (r S =0.48, P =0.0015) levels. Moreover, in DM patients with ILD, the cumulative survival rate for 6 months was significantly lower in the group with serum PGRN levels ≥200 ng/ml (67%) than in the group with serum PGRN levels <200 ng/ml (100%) (P =0.0009). Conclusions: Serum PGRN is associated with disease activity and prognosis of DM with ILD. PGRN may play a role in the pathogenesis of DM and could be a useful biomarker.

AB - Introduction: Progranulin (PGRN), a pleiotropic growth factor, has emerged as an immunoregulatory molecule. Because the roles of PGRN in dermatomyositis (DM) are still unknown, we investigated whether serum PGRN levels are associated with disease activity and prognosis in DM patients, particularly in those with DM complicated with interstitial lung disease (ILD). Methods: The serum levels of PGRN were measured by enzyme-linked immunosorbent assay in patients with DM (n =57; acute/subacute interstitial pneumonia (A/SIP): n =17, chronic interstitial pneumonia (CIP): n =24, without ILD: n =16), polymyositis (PM, n =21; including 6 with ILD) and normal healthy controls (NHCs, n =60). We assessed the correlation between the serum PGRN levels and the activity indexes of ILD or prognosis in DM patients with ILD. Results: Serum PGRN levels were significantly higher in DM patients than in PM patients (P =0.0025) and in NHCs (P <0.0001). In DM patients, the levels were significantly higher in patients with A/SIP than in those with CIP (P <0.0001) or without ILD (P =0.0003). The serum PGRN levels in DM patients with ILD significantly correlated with serum ferritin (r S =0.77, P <0.0001), lactate dehydrogenase (r S =0.54, P =0.0003) and C-reactive protein (r S =0.48, P =0.0015) levels. Moreover, in DM patients with ILD, the cumulative survival rate for 6 months was significantly lower in the group with serum PGRN levels ≥200 ng/ml (67%) than in the group with serum PGRN levels <200 ng/ml (100%) (P =0.0009). Conclusions: Serum PGRN is associated with disease activity and prognosis of DM with ILD. PGRN may play a role in the pathogenesis of DM and could be a useful biomarker.

UR - http://www.scopus.com/inward/record.url?scp=84928776633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928776633&partnerID=8YFLogxK

U2 - 10.1186/s13075-015-0547-z

DO - 10.1186/s13075-015-0547-z

M3 - Article

C2 - 25888887

AN - SCOPUS:84928776633

VL - 17

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

M1 - 27

ER -